Please assess the completion status of the following clinical trial:

Trial Title: DIA_CENTRAL:T2D Treatment Pattern in Central Europe

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent prior to participation~2. Female and male patients age ≥ 18 years~3. Patients with T2D diagnosis~4. Patients who have been newly initiated (first ever use) with empagliflozin or other Sodium Glucose Transporter 2 inhibitor (SGLT2i), Dipeptidyl-peptidase 4 inhibitor (DPP4i) or Glucagon-like peptide 1 agonist (GLP1a) between September 2018 and December 2018 (study index date 1)~5. Patients have been naïve to treatment with empagliflozin or other Sodium Glucose Transporter 2 inhibitor (SGLT2i), Dipeptidyl-peptidase 4 inhibitor (DPP4i) or Glucagon-like peptide 1 agonist (GLP1a) at study index date 1~Exclusion Criteria:~1. Patients age \< 18 years~2. Patients with diagnosis of other types of diabetes than T2D~3. Patients who do not provide written consent to the terms of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Subjects with Diabetes Mellitus, Type 2 (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).